Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis

  • 1,
  • 1,
  • 1Email author,
  • 2,
  • 1,
  • 3,
  • 1 and
  • 1
Contributed equally
BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:306

https://doi.org/10.1186/s12879-016-1625-9

  • Received: 6 February 2016
  • Accepted: 7 June 2016
  • Published:
Open Peer Review reports

Abstract

Background

Awareness about paradoxical reactions in tuberculous meningitis is crucial as a paradoxical reaction may lead to certain wrong conclusions (for example, an erroneous diagnosis, and a possibility of treatment failure, mycobacterial drug-resistance, drug toxicity, or presence of a malignancy). The present study was planned to evaluate the incidence and predictive factors of paradoxical reactions in light of clinical, cerebrospinal fluid, and neuroimaging characteristics.

Methods

In this prospective cohort study, consecutive patients fulfilling the International Consensus criteria of tuberculous meningitis were included. Patients were subjected to clinical evaluation, cerebrospinal fluid evaluation, and neuroimaging. Patients were treated with anti-tuberculosis drugs along with corticosteroids. Patients were regularly followed up at 3 monthly intervals. At each follow up patients were evaluated clinically and repeat cerebrospinal fluid analysis was performed along with repeat neuroimaging. Disability assessment was done using Barthel index.

Results

We enrolled 141 patients of tuberculous meningitis. Approximately one-third of patients (44/141; 31.2 %) developed a paradoxical reaction. Twenty-seven patients developed hydrocephalus, 26 developed tuberculomas, 12 developed optochiasmatic arachnoiditis and 4 patients had spinal arachnoiditis. In 41 patients (out of 44) cerebrospinal fluid paradoxically worsened (increase in cells and/or protein); 2 demonstrated a decrease in cells with polymorph predominance while in one it was normal. In 3 patients, paradoxical cerebrospinal fluid changes were not associated with neuroimaging changes. On multivariate analysis, predictors of paradoxical reaction were female gender (p = 0.013), HIV positivity (p = 0.01) and a shorter duration of illness (p = 0.049). Development of paradoxical reactions did not predict the disability status of the patients.

Conclusions

Paradoxical reaction occurs in approximately one-third of patients with tuberculous meningitis. Female gender, concomitant HIV infection, and a shorter duration of illness were significant predictors. Paradoxical reactions did not adversely affect the outcome.

Keywords

  • Tuberculoma
  • Optochiasmatic arachnoiditis
  • Hydrocephalus
  • Cerebrospinal fluid
  • Immune reconstitution inflammatory syndrome

Background

Paradoxical reaction, in patients with tuberculous meningitis, is characterized by either worsening of pre-existing tuberculous lesions or the appearance of new tuberculous lesions in patients who show initial improvement following anti-tuberculosis treatment. The clinical or radiological deterioration associated with such a reaction may fallaciously suggest either a drug resistant state or treatment failure, and might even prompt to look for an alternative diagnosis [13]. The manifestations of paradoxical reaction, that have been described, are mostly derived from case reports and small case series. These include a variety of clinical manifestations and neuroimaging abnormalities, along with an altered cerebrospinal fluid picture. Cerebrospinal fluid changes may include lymphocytic pleocytosis, a change in cellular components in the direction of polymorphonuclear predominance, or an increase in protein levels. Paradoxical reaction does not necessarily represent treatment failure and corticosteroids have been shown to have a beneficial effect [46].

In human immunodeficiency virus (HIV)-infected patients, paradoxical reactions are termed as the immune reconstitution inflammatory syndrome (IRIS), which is a condition characterized with worsening of pre-existing infective processes, following treatment with antiretroviral therapy. Tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by worsening of clinical symptoms, signs, and imaging characteristics of tuberculosis subsequent to initiation of antiretroviral therapy after initial improvement with anti-tuberculosis treatment [7, 8].

Most of the current information about paradoxical reaction in tuberculous meningitis is in the form of isolated case reports, small case series, and articles with small number of patients. The exact frequency and spectrum of paradoxical reaction is not precisely known. Its impact on prognosis is also not clear. This prospective follow up study has been planned to answer all these questions.

Methods

This prospective study was conducted in Department of Neurology, King George Medical University Uttar Pradesh, Lucknow. Our institute is a tertiary care hospital serving a population of approximately 100 million. It is situated in an area which is highly endemic for tuberculosis. Formal ethical approval was taken from the Institutional Ethics Committee, King George’s Medical University, U.P., India. Written informed consent was obtained from all patients and/or their legal guardians.

Inclusion criteria

All consecutive newly-diagnosed patients of tuberculous meningitis, fulfilling the consensus diagnostic criteria as described by Marais et al., were included. Patients were categorized into definite, probable, or possible tuberculous meningitis groups on the basis of clinical, imaging, and laboratory criteria. The definite cases of tuberculous meningitis had either the presence of acid-fast bacilli in cerebrospinal fluid, or mycobacterium could be cultured from cerebrospinal fluid, or cerebrospinal fluid was positive for mycobacterial nucleic acids by polymerase chain reaction. The probable cases fulfilled the clinical entry criteria plus a total diagnostic score of 10 or more points (when cerebral imaging was not available) or 12 or more points (when cerebral imaging was available) plus exclusion of alternative diagnoses. The possible cases included clinical entry criteria plus a total diagnostic score of 6–9 points (when cerebral imaging was not available) or 6–11 points (when cerebral imaging was available) along with the exclusion of alternative diagnoses [9].

Disease severity

Patients were classified as per British Medical Research Council staging system. Patients with stage-I disease had a Glasgow Coma Scale score of 15 with no focal neurologic signs; patients with stage-II had signs of meningeal irritation with slight or no alteration of sensorium and minor neurological deficit (like cranial nerve palsies) or no deficit (Glasgow coma scale score 11 to14), and patients with stage-III had severe alteration of sensorium, convulsions, focal neurological deficit and involuntary movements (Glasgow coma scale score <10) [10].

Evaluation of patients

All enrolled patients were subjected to detailed clinical, radiological, and laboratory evaluation. Occurrence of systemic tuberculosis, such as involvement of pulmonary system, lymph node, bone, and other organs, were recorded. The work up included complete blood count, peripheral blood smear examination, erythrocyte sedimentation rate, blood urea nitrogen, blood sugar, serum creatinine, serum electrolytes, liver function tests, chest X-ray, and enzyme linked immunosorbent assay for HIV. Cerebrospinal fluid biochemical and microscopic examination, including India ink preparation, were performed. Cerebrospinal fluid sediments were stained, cultured (Lowenstein Jensen media), and tested for drug susceptibility by standard methods. Cerebrospinal fluid specimens were also tested for mycobacterial nucleic acids by polymerase chain reaction. Appropriate patients were also evaluated by performing bacterial screen with culture, cryptococcal latex antigen detection, antinuclear antibody, antineutrophil cytoplasmic antibody screen, hepatitis B and C, and angiotensin converting enzyme level. Patients were subjected to MR imaging of the brain and/or spinal cord using Signa Excite 1.5 Tesla instrument (General Electric Medical Systems, Milwaukee, WI, USA.

Exclusion criteria

Patients with cryptococcal meningitis or any other cause for meningitis were excluded from the study.

Definition of paradoxical reaction

A paradoxical reaction was defined as the worsening of pre-existing tuberculous lesions or the appearance of new tuberculous lesions in patients whose clinical symptoms initially improved and had been on anti-tuberculosis treatment for at least 10 days [2, 3, 11]. For the purpose of the calculation of “time of onset of paradoxical reaction” in the study participants only clinical deteriorations were considered from the time of initiation of anti-tuberculosis treatment; non-symptomatic radiological worsening was defined either at the time of clinical deteriorations or at the pre-defined follow-up visit.

Definition of other neuroimaging findings

Hydrocephalus was defined as ventriculomegaly with Evan’s ratio (maximal width of frontal horns/maximal width of inner skull) of more than 30 % and/or size of one or both temporal horns greater than 2 mm. Communicating hydrocephalus was characterized with ventriculomegaly with a dilated fourth ventricle. Meningeal inflammation, on gadolinium-enhanced MRI, was defined as an enhancement of pia-arachnoid mater covering subarachnoid spaces of the sulci and basal cisterns. Exudates were defined as a thick area of enhancement, predominantly in basal cisterns and Sylvian fissure. Optochiasmatic tuberculoma and arachnoiditis were characterized with confluent enhancing lesions involving interpeduncular fossa, pontine cistern, and perimesencephalic and suprasellar cisterns. Spinal arachnoiditis was defined with the presence of enhancement of spinal meninges, and nerve roots, obliteration of the spinal subarachnoid space, cysts and loculations in subarachnoid space, or syrinx formation. Tuberculomas were defined as discrete or coalescing cerebral masses showing nodular or ring shaped enhancement. Infarcts were areas of abnormal signal intensity in a vascular distribution, predominantly in periventricular region. Infarcts appeared hyperintense on T2-weighted images and hypointense on T1-weighted images, with corroborating changes on diffusion-weighted and apparent diffusion coefficient images.

Treatment

All included patients received anti-tuberculosis treatment as per World Health Organization guidelines for the treatment of central nervous system tuberculosis. Patients received 2 months of daily oral isoniazid (5 mg/ kg of body weight; maximum, 300 mg), rifampicin (10 mg/ kg; maximum, 600 mg), pyrazinamide (25 mg/kg; maximum, 2 g/day) and intramuscular streptomycin (20 mg/kg; maximum 1 gm/day), followed by at least 7 months administration of isoniazid and rifampicin [12]. Corticosteroid regimen consisted of intravenous dexamethasone for 4 weeks (0.4 mg/kg body weight per day and then tapered off decreasing 0.1 mg/kg every week) and then oral treatment for 4 weeks, starting at a total of 4 mg per day and decreasing by 1 mg each week [13]. Pyridoxine was given orally 20–40 mg/day to all the patients. In addition, patients received symptomatic treatment as well. Neurosurgical opinion was sought, whenever required.

In HIV-infected patients antiretroviral therapy was administered under supervision of the Nodal anti-retroviral therapy unit. Antiretroviral therapy was started as soon as anti-tuberculosis treatment was tolerated (between 2 weeks and 2 months), as per National AIDS Control Organization, Government of India, guidelines [14].

Disability assessment

Disability assessment was done using Barthel index (BI), which is a 20 point scoring system. Assessment of disability included degree of dependence for bowel and bladder, grooming, toilet use, transfer, mobility, dressing, feeding, use of stairs and bathing. For each activity, a score of 0 indicated a complete dependence, and an individual score of 2 or 3 indicated that the patient was able to perform activities independently. A score of ≤ 12 indicated poor functional status and a score of >12 indicated good functional status.

Follow up

Patients were regularly followed up for 9 months. Besides a defined follow up at 3, 6, and 9 months, clinical assessment and cerebrospinal fluid analysis were also done at the time of clinical deterioration. Changes in cerebrospinal fluid parameters (like cells, protein and sugar) were noted. Polymorphonuclear predominance was defined when these constituted >50 % of cells. Repeat neuroimaging were performed after 3 months and 6 months, or at periods of clinical deteriorations. Neuroimaging were looked for any deterioration or new findings. Assessment of disability was done at the end 9 months of follow up. Barthel index >12 was considered as good outcome. Intervening visits mandated by clinical deteriorations generated off-pre-defined visit data which was additionally recorded.

Statistical analysis

Statistical analysis was performed using the Statistical Package for Social Sciences, version 16 for windows (SPSS, Chicago IL, USA). Both univariate and multivariate analysis were done to evaluate the predictors of paradoxical reaction. Univariate analysis was performed by Chi-square test for categorical variables and independent sample “t” test for continuous variables. Odds ratio with 95 % confidence interval were ascertained. For multivariate analysis, binary logistic regression was performed to see the impact of individual predictors of paradoxical reaction. Paired sample “t” test and McNemar tests were used to compare quantitative and qualitative variables before and during development of paradoxical reaction. Kaplan Meier analysis was performed to estimate the event free survival for the outcome with or without baseline paradoxical reaction using the Log Rank test. Statistical significance was defined at a p value of <0.05. All statistical analyses were two-tailed.

Results

Baseline characteristics

We screened 156 consecutive patients of tuberculous meningitis during the study period which ranged from October 2013 to March 2015. Fifteen patients were excluded. Reasons for exclusion of 15 patients have been provided in Fig. 1. Finally, 141 patients were included and evaluated. Majority of our patients 66 (46.8 %), at inclusion, were in stage-II. Thirteen patients were HIV positive. There were 54 (38.3 %) microbiologically-confirmed cases. One patient had multidrug resistant tuberculous meningitis and was included in the non-paradoxical reaction group. In the paradoxical reaction group the mean duration of illness was 42.93 ± 21.58 (median = 38, range 18–107) days while in the non-paradoxical reaction group the mean duration of illness was 52.49 ± 27.54 (median = 45, range 5–180) days (Table 1).
Fig. 1
Fig. 1

Flow chart of the study

Table 1

Baseline characteristics, radiological and cerebrospinal fluid parameters, and outcome of patients with tuberculous meningitis

 

Total numbers of patients included (n=141)

Paradoxical manifestation (n=44)

No paradoxical manifestation (n=97)

Demographic

 Age (Mean±SD)

29.75±12.79

27.295±10.95

30.866±13.44

 Duration of illness (Mean±SD)

49.51±26.13

42.932±21.58

52.495±27.53

 Gender (n, %)

   

 Male

76(53.9 %)

18(40.9 %)

58(59.8 %)

 Female

65(46.1 %)

26(59.1 %)

39(40.2)

 HIV (n, %)

13(9.2 %)

11(25 %)

2(2.1 %)

Clinical (n, %)

 BMRC stage 1

31(22.0 %)

8(18.2 %)

23(23.7 %)

 BMRC stage 2

66(46.8 %)

21(47.7 %

45(46.4 %)

 BMRC stage 3

44(31.2 %)

15(34.1 %)

29(29.9 %)

 Fever

138(97.8 %)

43(97.7 %)

95(97.9 %)

 Headache

131(92.90 %)

39(88.6 %)

92(94.8 %)

 Seizure

48(34.0 %)

12(27.3 %)

36(37.1 %)

 Altered Sensorium

44(31.2 %)

15(34.1 %)

29(29.9 %)

 Decreased vision

35(24.8 %)

10(22.7 %)

25(25.8 %)

 Hemiparesis

23(16.3 %)

7(15.9 %)

16(16.5 %)

 Paraparesis

12(8.5 %)

2(4.5 %)

10(10.3 %)

 Meningeal signs

125(88.7 %)

41(93.2 %)

84(86.6 %)

 Lymphadenopathy

13(9.2 %)

10(22.7 %)

3(3.1 %)

 Diplopia

59(41.8 %)

17(38.6 %)

42(43.3 %)

 Cranial Nerve involvement

80(56.7 %)

27(61.4 %)

53(54.6 %)

 Papilloedema

50(62.5 %)

13(29.5 %)

42(43.3 %)

Imaging (n, %)

 Hydrocephalus

53(37.6 %)

13(29.5 %)

40(41.2 %)

 Basal Exudates

38(27.0 %)

9(20.5 %)

29(29.9 %)

 Tuberculoma

51(36.2 %)

15(34.1 %)

36(37.1 %)

 Infarct

25(17.7 %)

7(15.9 %)

18(18.6 %)

 Optochiasmatic arachnoiditis

21(14.9 %)

7(15.9 %)

14(14.4 %)

 Spinal arachnoiditis

12(8.5 %)

2(4.5 %)

10(10.3 %)

Cerebrospinal fluid

 White blood cells (cells/mL±SD)

189.610±185.66

200.864±121.26

184.505±208.809

 Protein mg%

253.704±455.84

188.5382±115.145

283.2649±542.511

 Sugar mg%

35.311±18.46

33.620±18.231

36.086±18.61

 Neutrophil differential in percentage, mean±SD

17.21±19.250

19.705±21.368

16.072±18.210

 Lymphocyte differential in percentage (mean±SD)

83.65±18.02

80.295±21.368

85.175±16.166

 AFB smear (n, %)

4(2.8 %)

1(2.27 %)

3(3.09 %)

 AFB culture positive (n, %)

21(14.9 %)

11(25 %)

10(10.30 %)

 TB PCR-positive (n, %)

50(35.5 %)

22(50 %)

28(28.86 %)

Diagnostic category (n, %)

 Definite

54(38.3 %)

20(45.5 %)

34(35.1 %)

 Probable

62(44.0 %)

19(43.2 %)

43(44.3 %)

 Possible

25(17.7 %)

5(11.4 %)

20(20.6 %

Disability (n, %)

 Baseline BI(<12)

93(66.0 %)

34(77.3 %)

59(60.8 %)

 Baseline BI(>12)

48(34.0 %)

10(22.7 %)

38(39.2 %)

Outcome (n, %)

 Poor (BI<12)

50(35.5 %)

12(27.3 %)

38(39.2 %)

 Good (BI>12)

91(64.5 %)

32(72.7 %)

59(60.8 %)

AFB acid fast bacilli, BMRC British Medical Research Council, HIV human immunodeficiency virus, BI Barthel index, TB PCR tuberculosis polymerase chain reaction

Incidence of paradoxical reaction

In our study, 44 (31.2 %) patients developed some form of paradoxical reaction. In majority (29 patients), paradoxical reactions were noted within 3 months of start of anti-tuberculosis treatment. Mean duration of paradoxical reaction was 82.45 days (16–320 days) (Additional file file 1: Table S1).

Manifestations of paradoxical reaction

Fever, headache, altered sensorium, decreased vision, and seizures were common clinical paradoxical reactions among 44 patients who presented with a paradoxical reaction. Among neuroimaging changes, enhancing basal exudates, a new or enlargement of pre-existing tuberculoma, development of infarcts, and increasing ventriculomegaly were the more frequent paradoxical reactions. Twenty-six (59 %) patients developed either a new (15 patients) or enlargement (11 patients) of pre-existing tuberculoma. Twenty patients demonstrated newly developed hydrocephalus while in 7 cases ventricular size had increased further. Optochiasmatic arachnoiditis was the other common but disabling paradoxical manifestation. Four patients, additionally, had spinal arachnoiditis. In 41 patients, cerebrospinal fluid paradoxically worsened (increase in cells with or without rise in protein level). Out of the remaining 3, two patients demonstrated a decrease in the cell count but with polymorph predominance (not present at the baseline) while in one the cerebrospinal fluid was normal. In cerebrospinal fluid, major changes observed were increase in protein level and increase in polymorphs. In 3 patients with paradoxical reaction, only cerebrospinal fluid changes (without imaging changes) were noted. Fourteen patients had paradoxical lymphadenopathy while three patients had developed miliary tuberculosis (Fig. 2) (Additional file 1: Table S1). Statistically significant changes from the baseline to the time of development of paradoxical reaction was observed in fever, headache, hydrocephalus, tuberculoma, c-reactive protein, erythrocyte sedimentation rate, and cerebrospinal fluid polymorphs, lymphocytes, and protein (Table 2).
Fig. 2
Fig. 2

T1-weighted Gadolinium-enhanced MRI (axial sections) of the brain of a patient with TBM depict the development of additional (paradoxical) tuberculoma (Baseline-a, at 5th month-b) at the pontocerebellar level. Similar sequence in another patient shows development of paradoxical optochiasmatic arachnoiditis along with multiple tuberculomas (Baseline-c, at 3rd month-d)

Table 2

Comparative analysis of variables of patients with paradoxical reaction

Variable

At baseline

During pxaradoxical reaction

P value

Fever

43

29

.001

Headache

39

27

.008

Seizure

12

11

1.0

Altered Sensorium

15

12

.664

Decreased vision

10

16

.180

Hemiparesis

7

9

.791

Paraparesis

2

4

.688

Hydrocephalus

13

27

.009

Tuberculoma

15

26

.019

Basal Exudate

9

12

.648

Optochiasmatic arachnoiditis

7

12

.332

Infarct

7

9

.791

Spinal arachnoiditis

2

4

.688

CRP

19

28

.004

ESR

27.818±4.876

33.20±5.889

.027

CSF cells

200.864±121.260

210.295±125.761

.058

CSF Polymorph

19.705±21.368

37.84±23.716

.008

CSF Lymphocytes

80.295±21.368

62.39±23.398

.012

CSF Protein

188.538±115.145

261.355±152.0650

<.001

CSF sugar

33.620±43.2566

43.256±17.998

.261

CRP C-reactive protein, CSF cerebrospinal fluid, ESR Erythrocyte sedimentation rate

Note: Statistically significant P-values are depicted in italics

Predictors of paradoxical reaction

On univariate analysis, female gender (p = 0.037), HIV positivity (p = <0.001), lymphadenopathy (p = 0.001) and a shorter duration of illness (p = 0.028) were significantly associated with development of paradoxical reaction (Table 3). On multivariate analysis, female gender (p = 0.013, OR =2.87, CI 1.24-6.62), HIV positivity (p = 0.010, OR = 31.49; CI = 2.31-426.21), and a shorter duration of illness (p = 0.049, OR = 0.98 CI = .963-1.00) were found to be statistically significant predictors of paradoxical reaction (Table 4).
Table 3

Predictors of paradoxical reaction on univariate analysis

Characteristic

Paradoxical reaction

P value

Odds ratio

95 % Confidence interval

Present (n=44)

Absent (n=97)

Lower bound

Upper bound

Age in years Mean ± SD

27.295 ± 10.958

30.866 ± 13.446

0.125

 

−1.004

8.145

Duration of illness (days) Mean ± SD

42.932± 21.583

52.495± 27.538

0.028

 

0.276

18.850

Gender (female)

26 (59.1 %)

39 (40.2 %)

0.037

2.148

1.04

4.436

HIV positive

11(25 %)

2(2.1 %)

<0.001

15.833

3.334

75.184

Fever

43(97.7 %)

95(97.9 %)

0.936

0.905

0.080

10.255

Headache

39(88.6 %)

92(94.8 %)

0.183

0.424

0.116

1.548

Seizure

12(27.3 %)

36(37.1 %)

0.253

0.635

0.291

1.387

Altered Sensorium

15(34.1 %)

29(29.9 %)

0.618

1.213

0.567

2.593

Decreased vision

10(22.7 %)

25(25.8 %)

0.698

0.847

0.366

1.960

Hemiparesis

7(15.9 %)

16(16.5 %)

0.930

0.958

0.363

2.526

Paraparesis

2(4.5 %)

10(10.3 %)

0.341

0.414

0.087

1.976

Meningeal signs

41(93.2 %)

84(86.6 %)

0.253

2.115

0.571

7.837

Lymphadenopathy

10(22.7 %)

3(3.1 %)

0.001

9.216

2.393

35.496

Diplopia

17(38.6 %)

42(43.3 %)

0.603

0.825

0.398

1.707

Cranial Nerve involvement

27(61.4 %)

53(54.6 %)

0.455

1.319

0.638

2.727

Papilloedema

13(29.5 %)

42(43.3 %)

0.121

0.549

0.256

1.177

Hydrocephalus

13(29.5 %)

40(41.2 %)

0.184

0.598

0.279

1.282

Basal Exudates

9(20.5 %)

29(29.9 %)

0.242

0.603

0.257

1.413

Tuberculoma

15(34.1 %)

36(37.1 %)

0.729

0.876

0.415

1.850

Infarct

7(15.9 %)

18(18.6 %)

0.703

0.830

0.319

2.161

Optochiasmatic Arachnoiditis

7(15.9 %)

14(14.4 %)

0.820

1.122

0.418

3.008

Spinal cord

2(4.5 %)

10(10.3 %)

0.256

0.414

0.087

1.976

CRP

19(43.2 %)

38(39.2 %)

0.653

1.180

0.573

2.430

Stage 3 TBM

15(34.1 %)

29(29.9 %)

0.618

1.213

0.567

2.593

Baseline BI (<12)

34(77.3 %)

59(60.8 %)

0.056

2.190

0.970

4.944

Definite TBM

20(45.5 %)

34(35.1 %)

0.312

1.544

.748

3.189

Good outcome (BI>12)

32(72.7 %)

59(64.8 %)

0.171

0.582

0.267

1.268

ESR mm in 1 h Mean ± SD

27.818 ± 4.876

27.093 ± 7.593

0.497

 

−3.194

1.743

CSF Cells/μL Mean ± SD

200.864 ± 121.261

184.505 ± 208.810

0.630

 

83.265

56.548

CSF protein (mg/dl) Mean ± SD

188.5382 ± 115.145

283.2649 ± 542.511

0.254

 

−68.924

258.377

CSF sugar (mg/dl) Mean ± SD

33.620 ± 18.231

36.086 ± 18.617

0.465

 

4.193

9.125

BI Barthel Index, CRP C-reactive protein, CSF cerebrospinal fluid, ESR Erythrocyte sedimentation rate, HIV Human Immunodeficiency Virus, TBM Tuberculous meningitis

Note: Statistically significant P-values are depicted in italics

Table 4

Predictors of paradoxical reaction on multivariate analysis

Characteristic

P value

Odds ratio

95 % Confidence interval

Lower bound

Upper bound

Duration

.049

.981

0.963

1.000

Gender (female)

.013

2.873

1.246

6.626

HIV

.010

31.407

2.314

426.215

Lymphadenopathy

.813

0.746

0.066

8.465

HIV human immunodeficiency virus

Note: Statistically significant P-values are depicted in italics

Impact on prognosis

Overall, duration of illness, alteration in consciousness, stage-III of tuberculous meningitis, and hydrocephalus predicted poor prognosis among patients with tuberculous meningitis. In the paradoxical group 24 % patients had poor outcome compared to 35.2 % with good outcome, which was statistically not significant (Table 5). We did not observe any significant difference in the proportion of patients having poor disability status after end of follow up. Kaplan-Meier survival statistics did not demonstrate any significant difference in survival between both groups (Fig. 3).
Table 5

Predictors of disability and outcome on univariate analysis in patients with tuberculous meningitis

Characteristics

BI≤12 (n=50)

BI>12 (n=91)

P value

Odds Ratio

95 % Confidence interval

Lower bound

Upper bound

Age

29.320±11.881

29.989±13.322

.768

 

−3.797

5.135

Duration of illness

42.140±21.204

53.560±27.761

.013

 

2.495

20.345

Gender

22(44 %)

54(59.3 %)

.080

.538

.268

1.082

HIV

      

Fever

49(98 %)

89(97.8 %)

.938

1.101

.097

12.453

Headache

44(88 %)

87(95.6 %)

.092

.337

.090

1.257

Seizure

15(30.0 %)

33(36.3 %)

.453

.753

.359

1.580

Altered Sensorium

31(62.0 %)

13(14.3 %)

<.001

9.789

4.316

22.206

Decreased vision

16(32.0 %)

19(20.9 %)

.144

1.783

.817

3.891

Hemiparesis

9(18.0 %)

14(15.4 %)

.688

1.207

.482

3.027

Paraparesis

6(12.0 %)

6(6.6 %)

.271

1.932

.588

6.342

Meningeal signs

44(88.0 %)

81(89 %)

.856

.905

.308

2.657

Lymphadenopathy

4(8.0 %)

9(9.9 %)

.711

.792

.231

2.716

Diplopia

19(38.0 %)

40(44.0 %)

.493

.821

.402

1.675

Cranial Nerve involvement

28(56.0 %)

52(57.1 %)

.896

.955

.476

1.914

Papilloedema

18(36.0 %)

37(40.7 %)

.587

.821

.402

1.675

Hydrocephalus

40(80.0 %)

13(14.3 %)

<.001

24.0

9.677

59.520

Basal Exudates

12(24.0 %)

26(28.6 %)

.558

.789

.357

1.744

Tuberculoma

22(44.0 %)

29(31.9 %)

.151

1.680

.825

3.422

Infarct

9(18.0 %)

16(17.6 %)

.950

1.029

.418

2.533

Optochiasmatic arachnoiditis

7(14.0 %)

14(15.4 %)

.825

.895

.336

2.388

Spinal arachnoiditis

6(12.0 %)

6(6.6 %)

.271

1.932

.588

6.342

Stage-III TBM

31(62.0 %)

13(14.3 %

<.001

9.789

4.316

22.206

Definite TBM

23(46.0 %)

31(34.1 %)

.163

   

Paradoxical reaction

12(24.0 %)

32(35.2 %)

.171

.582

.267

1.268

CSF Cells

159.340

206.242

.152

 

−17.474

111.277

CSF protein

256.772

252.019

.953

 

−163.99

154.488

CSF sugar

35.112

35.422

.925

 

−6.153

6.773

CSF cerebrospinal fluid, HIV human immunodeficiency virus, BI Barthel index, TBM tuberculous meningitis

Note: Statistically significant P-values are depicted in italics

Fig. 3
Fig. 3

Kaplan Meyer survival analysis showed no significant difference in the cumulative survival of patients with or without paradoxical reaction (Log rank test: X2 (1) = 2.198, P = 0.138)

Discussion

In this prospective study approximately one-third of patients with tuberculous meningitis developed paradoxical changes. In almost all patients, clinical/imaging paradoxical manifestations accompanied paradoxical cerebrospinal fluid changes. We encountered a variety of manifestations of paradoxical reactions. These paradoxical clinical and neuroimaging manifestations were either aggravated or appeared for the first time during illness, despite of an adequate anti-tuberculosis treatment. Expansion of existing cerebral tuberculomas and appearance of new tuberculomas, hydrocephalus, and optochiasmatic and spinal arachnoiditis, were common paradoxical manifestations.

Paradoxical reactions in these patients result because of an excessive inflammatory response against mycobacterial antigens. Mycobacterial cell wall antigens are present in the affected brain tissues and trigger an exaggerated inflammatory reaction following treatment with anti-tuberculosis drugs. Cheng and colleagues had noted a surge in blood lymphocyte counts accompanied by an increased tuberculin skin reaction during paradoxical response indicating that this immune response is similar to immune restoration syndrome seen in HIV-infected patients. Possibly, due to a paradoxical shift in the cellular components of the cerebrospinal fluid (from lymphocytic predominance to polymorph predominance), neutrophils also play a role in the pathogenesis of paradoxical reaction in patients with tuberculous meningitis. [15] Sütlaş and co-workers followed 61 patients with confirmed or presumed tuberculous meningitis. Patients were categorized into two groups according to the presence of paradoxical response (progressive increase of lymphocytes or increase of polymorphonuclear cells instead of lymphocytes) in cerebrospinal fluid samples. Paradoxical response in the cerebrospinal fluid was seen in 20 patients. New tuberculomas developed more frequently in the group having paradoxical cerebrospinal fluid response. We had similar observations in our study where 41 patients with clinical/imaging paradoxical changes had paradoxical cerebrospinal fluid changes. Interestingly, in two patients where the cells actually decreased, there was a shift towards polymorph predominance. It has been observed that paradoxical cerebrospinal fluid changes occur after several weeks of starting anti-tuberculosis treatment and may not be associated with any clinical or neuroimaging deterioration [16].

We observed that female gender, concomitant HIV infection, and a shorter duration of illness, were significant predictors of paradoxical reactions in patients with tuberculous meningitis. Females exhibit more-robust immune responses to antigenic challenges, like infection and vaccination, in comparison to that in males. Given the fact that immune cells express specific receptors for sex hormones and are responsive to changes in hormone levels, this gender variation might be explained by the modulatory effect of female sex hormones on the immune response towards Mycobacterium tuberculosis associated antigens [17, 18].

Patients with disseminated or extrapulmonary disease are considered to have higher bacillary/antigen loads, with a relative immunodeficient response, resulting in an increased risk of both paradoxical reactions and IRIS. Use of bactericidal drugs, such as isoniazid, may cause a massive release of bacterial components and provoke inflammatory changes that could produce clinical deterioration and imaging changes [19]. Another significant predictor of paradoxical reaction was a shorter duration of illness. Possibly, a large mycobacterial load and subsequent release of mycobacterial antigen following anti-tuberculosis treatment resulted in a higher frequency of paradoxical reactions among patients who developed tuberculous meningitis comparatively rapidly.

A substantial proportion of our HIV-infected patients (11 out of 13 patients) developed paradoxical reactions. Many studies in the past have noted that many patients develop tuberculous meningitis associated IRIS. Manifestations of central nervous system tuberculosis IRIS include meningitis, cerebral parenchymal tuberculoma, brain abscesses, spinal cord complications like myeloradiculopathy, and spinal epidural abscesses [2022]. In a prospective study, 47 % (16/34) of tuberculous meningitis patients developed tuberculous meningitis-IRIS. At inclusion, tuberculous meningitis-IRIS patients had a higher cerebrospinal fluid neutrophil counts compared with non-tuberculous meningitis-IRIS patients [20]. There is a consensus that antiretroviral therapy should be started early (around 2 weeks) in HIV/tuberculosis co-infected patients. In HIV and tuberculous meningitis co-infected patients, because of a potential risk of tuberculous meningitis associated IRIS, antiretroviral therapy may be delayed; however, there is no consensus on this point [23].

We observed that the development of paradoxical reactions did not adversely affect the outcome of tuberculous meningitis. Several studies in the past had similar observations. Clinical, laboratory, radiological, and outcome data of 14 cases of paradoxical tuberculoma in tuberculous meningitis patients (out of 22 patients who had intracranial tuberculoma) were compared with 41 tuberculous meningitis patients without tuberculomas. The analysis suggested that there was no statistical difference between two groups regarding age, stage of tuberculous meningitis, duration between disease onset and treatment initiation, cerebrospinal fluid protein levels, and in long-term disabilities [24]. Many manifestations of paradoxical reactions like optochiasmatic and spinal arachnoiditis, and a large cerebral tuberculoma are serious conditions associated with severe disabilities, and a potential for death [25]. These conditions warrant urgent treatment with immunomodulatory drugs. High doses of corticosteroids are currently the most preferred treatment. Many other immunomodulatory drugs like, tissue necrosis factor-α antagonists, thalidomide, and interferon– γ have also been used, though sparingly [3].

There were certain limitations of our study. It is difficult to pin-point exactly the timing of onset of a paradoxical reaction clinically. Besides this, the differential diagnosis of a paradoxical reaction may also pose a challenge. A wrong diagnosis, possibility of treatment failure, multidrug-resistance, atypical mycobacterial infection, drug toxicity, or clinical deterioration due to some unrelated cause should always be co-considered. One of our patients with apparent paradoxical reaction later turned out to have multidrug-resistant tuberculosis.

Conclusion

Paradoxical reaction occurs in approximately one-third of patients with tuberculous meningitis. Female gender, concomitant HIV infection, and a shorter duration of illness are significant predictors of such reactions. Duration of illness, alteration in consciousness, stage-III of tuberculous meningitis, and hydrocephalus, predict a poor prognosis in patients with tuberculous meningitis; paradoxical reactions, however, do not seem to affect the outcome adversely.

Abbreviations

AIDS, acquired immune deficiency syndrome; BI, barthel index; HIV, human immunodeficiency virus; IRIS, immune reconstitution inflammatory syndrome; MRI, magnetic resonance imaging

Declarations

Acknowledgement

None.

Funding

Funding was not obtained for this study.

Availability of data and materials

All the data supporting your findings is contained within the manuscript.

Authors’ contributions

AKS: concept of study, execution of study and data analysis and writing the manuscript. HSM: concept of study, execution of study and data analysis and writing the manuscript. RKG: concept of study, execution of study and data analysis and writing the manuscript. AJ: responsible for microbiological studies and manuscript writing. NK: concept of study, execution of study and data analysis and writing the manuscript. NK: responsible for conduct and assessment of Neuroimaging in the study. RV: patient evaluation and manuscript writing. PKS: patient evaluation and manuscript writing. All authors have read and approve of the final version of the manuscript.

Competing interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Consent for publish

Not applicable.

Ethics and consent to participate

Written informed consent was obtained from the patient from each patient or his/her legal guardian. The study was approved by the Institutional Ethics Committee, King George’s Medical University, U.P., India (Reference Code: 64th ECM II-B/P19).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurology, King George Medical University, Uttar Pradesh, Lucknow, PIN-226003, India
(2)
Department of Microbiology, King George Medical University, Uttar Pradesh, Lucknow, India
(3)
Department of Radiodiagnosis, King George Medical University, Uttar Pradesh, Lucknow, India

References

  1. Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis. 1994;19:1092–9.View ArticlePubMedGoogle Scholar
  2. Nicolls DJ, King M, Holland D, Bala J, del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis. 2005;5:795–801.View ArticlePubMedGoogle Scholar
  3. Garg RK, Malhotra HS, Kumar N. Paradoxical reaction in HIV negative tuberculous meningitis. J Neurol Sci. 2014;340:26–36.View ArticlePubMedGoogle Scholar
  4. Garcia-Monco JC, Ferreira E, Gomez-Beldarrain M. The therapeutic paradox in the diagnosis of tuberculous meningitis. Neurology. 2005;65:1991–2.View ArticlePubMedGoogle Scholar
  5. Teoh R, O'Mahony G, Yeung VT. Polymorphonuclear pleocytosis in the cerebrospinal fluid during chemotherapy for tuberculous meningitis. J Neurol. 1986;233:237–41.View ArticlePubMedGoogle Scholar
  6. Kim SH, Kim YS. Immunologic paradox in the diagnosis of tuberculous meningitis. Clin Vaccine Immunol. 2009;16:1847–9.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Meintjes G, Lawn SD, Scano F, Maartens G, French MA, Worodria W, Elliott JH, Murdoch D, Wilkinson RJ, Seyler C, John L, van der Loeff MS, Reiss P, Lynen L, Janoff EN, Gilks C, Colebunders R. International Network for the Study of HIV-associated IRIS. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8:516–23.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Marais S, Meintjes G, Pepper DJ, Dodd LE, Schutz C, Ismail Z, Wilkinson KA, Wilkinson RJ. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2013;56:450–60.View ArticlePubMedGoogle Scholar
  9. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10:803–12.View ArticlePubMedGoogle Scholar
  10. Council BMR. Streptomycin treatment of tuberculous meningitis. BMJ. 1948;1:582–97.View ArticleGoogle Scholar
  11. Hawkey CR, Yap T, Pereira J, Moore DA, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 2005;40:1368–71.View ArticlePubMedGoogle Scholar
  12. World Health Organization. Treatment of tuberculosis: guidelines. WHO/HTM/TB/2009.420. 4th ed. World Health Organization; 2012 [http://whqlibdoc.who.int/ publications/2010/9789241547833_eng.pdf; 2010; accessed on 9 January.2016]
  13. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741–51.View ArticlePubMedGoogle Scholar
  14. National AIDS Control Organization. National Guidelines on Second-line and Alternative First-line ART For Adults and Adolescents. Department of Health & Family Welfare Government of India New Delhi, India. Downloaded from http://www.naco.gov.in/upload/Policies%20&%20Guidelines/Antiretroviral%20Therapy%20Guidelines%20for%20HIV-Infected%20Adults%20and%20Adolescents.pdf Assessed on January 7, 2016.
  15. Cheng VC, Yam WC, Woo PC, Lau SK, Hung IF, Wong SP, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003;22:597–602.View ArticlePubMedGoogle Scholar
  16. Sütlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculous meningitis in adults: review of 61 cases. Infection. 2003;31:387–91.PubMedGoogle Scholar
  17. Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. J Infect Dis. 2014;209 Suppl 3:S100–6.View ArticlePubMedGoogle Scholar
  18. Neyrolles O, Quintana-Murci L. Sexual inequality in tuberculosis. PLoS Med. 2009;6, e1000199.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Bell LC, Breen R, Miller RF, Noursadeghi M, Lipman M. Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis. Int J Infect Dis. 2015;32:39–45.View ArticlePubMedGoogle Scholar
  20. Crump JA, Tyrer MJ, Lloyd-Owen SJ, Han LY, Lipman MC, Johnson MA. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis. 1998;26:1008–9.View ArticlePubMedGoogle Scholar
  21. Pepper DJ, Marais S, Maartens G, Rebe K, Morroni C, Rangaka MX, Oni T, Wilkinson RJ, Meintjes G. Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis. 2009;48(11):e96–107.View ArticlePubMedGoogle Scholar
  22. Marais S, Scholtz P, Pepper DJ, Meintjes G, Wilkinson RJ, Candy S. Neuroradiological features of the tuberculosis-associated immune reconstitution inflammatory syndrome. Int J Tuberc Lung Dis. 2010;14:188–96.PubMedPubMed CentralGoogle Scholar
  23. Lawn SD, Wood R. Poor prognosis of HIV-associated tuberculous meningitis regardless of the timing of antiretroviral therapy. Clin Infect Dis. 2011;52(11):1384–7.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Unal A, Sutlas PN. Clinical and radiological features of symptomatic central nervous system tuberculomas. Eur J Neurol. 2005;12:797–804.View ArticlePubMedGoogle Scholar
  25. Sinha MK, Garg RK, Anuradha HK, Agarwal A, Singh MK, Verma R, et al. Vision impairment in tuberculous meningitis: predictors and prognosis. J Neurol Sci. 2010;290:27–32.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement